Ocugen, Inc.

Ocugen to Participate in Upcoming November Investor and Industry Conferences

Ocugen announced it will present its modifier gene therapy platform at two November 2026 conferences. CEO Dr. Shankar Musunuri will present at the Stifel 2026 Healthcare Conference in New York on November 12 and join a panel at Cell & Gene Leaders Live 2026 in London on November 15. A webcast of the Stifel presentation will be available on the company's investor relations site with a 30-day replay.

•3d ago

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Ocugen will host a conference call and webcast on November 4, 2026 at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. This is a scheduling announcement only, with no financial results or new business developments disclosed. A replay and archived webcast will be available on the company's investor website after the call.

•10d ago

Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update

Hemostemix Inc. announced full Bahamas LARTA Board approval, including ethics approval, for a commercial Phase 1 study of VesCell as a treatment for angina, vascular dementia and pain. The release also details a non-brokered private placement of up to $1,000,000 at C$0.05 per unit, with an initial closing of C$380,500, plus a manufacturing update noting CytoImmune test batches of ACP-01 moving into the cleanroom and a decision not to proceed with the CytoImmune bioreactor licence. For Ocugen (OCGN), the filer, the only relevance is a passing mention that its OCU400 gene therapy received provisional LARTA approval and priority designation for retinitis pigmentosa on September 25, 2026 — no new OCGN disclosure is made.

•25d ago

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Ocugen appointed Jolanda Crombach, MSc PharmD, as General Manager of its newly established European affiliate headquartered in Amsterdam. Crombach brings more than 20 years of pharmaceutical experience, most recently building and leading Moderna's Netherlands affiliate, with prior roles at MSD and Pfizer. The affiliate will support upcoming European Marketing Authorization submissions, the OCU410 Phase 3 program, and potential commercialization of Ocugen's three late-stage blindness gene therapy programs, with key data readouts expected in 2027 and 2028.

•26d ago

Ocugen to Participate in Upcoming Scientific Conferences

Ocugen will present on its modifier gene therapy platform at Euretina 2026 in Vienna and the American Academy of Ophthalmology Annual Meeting in New Orleans. Presentations cover twelve-month Phase 2 ArMaDa data for OCU410 in geographic atrophy, GARDian1 Phase 1 results for OCU410ST in Stargardt disease, and three-year OCU400 data in retinitis pigmentosa. This is a visibility event with no new data disclosed; investors should watch presentation dates for incremental safety or efficacy color.

•1mo ago

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Ocugen announced its executive leadership will present at two October investor and industry conferences. CEO Dr. Shankar Musunuri will moderate a panel on alternative life-sciences financing at H.C. Wainwright's Biotech on Tap in Munich on October 1, and speak on cell and gene therapy commercialization at the Cell & Gene Meeting on the Mesa in Phoenix on October 6. The release contains no new clinical, regulatory, or financial information and is routine investor-relations scheduling.

•1mo ago

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Ocugen announced it will present at three upcoming conferences in September 2026, including the Citi 2026 Biopharma Back to School Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company also plans to present 12-month Phase 2 ArMaDa results for its OCU410 gene therapy for geographic atrophy at the Retina Society 59th Annual Scientific Meeting. Webcasts of the investor conferences will be available on the company's website.

•2mo ago

Ocugen to Participate in Upcoming August Investor Conferences

Ocugen announced its participation in two upcoming investor conferences scheduled for August 2026, where management will present on its modifier gene therapy platform. The Company is set to participate in a panel discussion titled "Beyond the Readout: Building Durable Value in Rare Diseases & Gen Meds" at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4. Dr. Shankar Musunuri, Chairman and CEO, will also hold a fireside chat at the Canaccord 46th Annual Growth Conference on August 11, which will be webcast on the company's website.

•3mo ago

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen announced it will host a conference call on August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a business update. The company confirmed it will issue a pre-market earnings announcement on the same day prior to the call.

•3mo ago

Ocugen to Participate in Upcoming July Industry Conferences

Ocugen announced its participation in three upcoming industry conferences in July 2026, including a fireside chat at the Piper Sandler Virtual Ophthalmology Day. At the ASRS annual meeting, external experts will present 1-year results from the Phase 2 ArMaDa trial of OCU410 and safety outcomes from the Phase 1/2 study. Company leadership and key opinion leaders will also discuss regenerative approaches in retinal disease at the OIS Retina Innovation Summit.

•4mo ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Ocugen announced it will present on its modifier gene therapy platform at three upcoming June 2026 conferences. The schedule includes the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 4, the Clinical Trials at the Summit panel on June 13, and the BIO International Convention on June 23. A webcast of the Noble presentation will be available on the company’s investor relations website for 30 days following the event.

•4mo ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen closed a private offering of $130 million in 6.75% Convertible Senior Notes due 2034, priced at 90% of par. The company received approximately $112.6 million in net proceeds after deducting discounts and expenses. Ocugen used $32.7 million of the proceeds to fully repay its loan with Avenue Capital Group, removing a restrictive debt facility. The remaining proceeds will be used for general corporate purposes, extending the company's cash runway into 2028 to support three late-stage clinical programs.

•5mo ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen priced a private offering of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, with a 13-day option for purchasers to buy an additional $15 million. The deal is expected to close on May 7, 2026, generating net proceeds of approximately $99.5 million, or up to $112.6 million if the option is fully exercised. The company plans to allocate about $32.7 million of the proceeds to fully repay its outstanding loan with affiliates of Avenue Capital Group, including accrued interest and related fees. Any remaining net proceeds will be used for general corporate purposes. The notes are convertible at an initial price of $2.68 per share, representing a 45% premium to the last reported sale price of $1.85 per share. Interest on the notes will be paid semi-annually at a rate of 6.75% per year.

•5mo ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Ocugen announced it will host a conference call on May 5, 2026, at 8:30 a.m. ET to discuss its first quarter 2026 financial results and business updates. The company intends to issue a pre-market earnings announcement on the same day, with a live webcast and replay available on its investor site. Ocugen is a biotechnology company focused on gene therapies for blindness diseases, targeting inherited retinal diseases, retinitis pigmentosa, Stargardt disease, and geographic atrophy.

•6mo ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen announced that CEO Dr. Shankar Musunuri and EVP Abhi Gupta will present at two upcoming April conferences: Oppenheimer's Innovation on the Island Biotech Summit in Puerto Rico and the Cell & Gene Meeting on the Mediterranean in Rome. Dr. Musunuri highlighted the company's planned BLA submission for OCU400 beginning later this year, describing its gene-agnostic approach as potentially first-in-class for treating blindness diseases. The company plans to provide updates on its modifier gene therapy platform and near-term catalysts during one-on-one meetings at the conferences.

•6mo ago